Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Gilead Sciences CEO Daniel O'Day said on CBS' "Face the Nation" Sunday that the company has donated its entire supply of the antiviral medication remdesivir to the federal government, which will determine which U.S. cities will receive the drug based on "urgent" need.

Why it matters: The FDA last week granted emergency use of remdesivir to treat coronavirus patients, but it has not granted official regulatory approval. Preliminary data indicates that the drug can help patients recover from the coronavirus more quickly than no treatment, but it does not significantly reduce death.

What they're saying: "We are grateful and really humbled that everything has moved so quickly," O'Day said. "It's only been three months since the first case was diagnosed in the United States to the emergency use authorization that was provided this past Friday. That's thanks to a lot of patients and caregivers that participate in our clinical trials."

  • "We are now firmly focused on getting this medicine to the most urgent patients around the country. We intend to get that to patients in the early part of this next week."

The big picture: O'Day said the federal government will decide which areas of the country need the drug most based on the number of ICU beds and "where the course of the epidemic is in the United States."

  • "[The federal government] will begin shipping tens of thousands of treatment courses out early this week and will be adjusting that as the epidemic shifts and evolves in different cities," he added.

Go deeper: Why Gilead's coronavirus drug is not a "silver bullet"

Go deeper

Updated Nov 9, 2020 - Health

23 states set single-day coronavirus case records last week

Data: Compiled by Axios; Map: Danielle Alberti/Axios

23 states set new highs last week for coronavirus infections recorded in a single day, according to the COVID Tracking Project (CTP) and state health departments. 15 states surpassed records from the previous week.

Why it matters: More states across the country are handling record-high caseloads than this summer.

Aug 11, 2020 - Health

Moderna reveals it may not hold patent rights for coronavirus vaccine

Photo: Maddie Meyer/Getty Images

Moderna said in new financial filings that it "cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications" — including the company's experimental coronavirus vaccine.

Why it matters: This disclosure comes six weeks after Axios and Public Citizen highlighted how the National Institutes of Health may hold joint ownership claims for this particular vaccine.

Aug 10, 2020 - Health

At least 48 local public health leaders have quit or been fired during pandemic

Former California public health director Dr. Sonia Angell on Feb. 27 in Sacramento, California. Photo: Justin Sullivan/Getty Images

At least 48 local and state-level public health leaders have retired, resigned or been fired across 23 states since April, according to a review by the AP and Kaiser Health News.

Driving the news: California public health director Dr. Sonia Angell resigned on Sunday without explanation, a few days after the state fixed a delay in reporting coronavirus test results that had affected reopenings for schools and businesses, AP reports.